Elliot Vesell

Q: What Schools Are Affiliated With Elliot Vesell

Elliot Vesell is affiliated with the following schools: Pennsylvania State University, Harvard University

Elliot Vesell's AcademicInfluence.com Rankings

Elliot Vesell

Medical

#945

World Rank

#1218

Historical Rank

#314

USA Rank

Pharmacology

#70

World Rank

#93

Historical Rank

#20

USA Rank

medical Degrees

Download Badge

Medical

Why Is Elliot Vesell Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Elliot Saul Vesell was an American pharmacologist. A New York City native born on December 24, 1933, Vesell attended Horace Mann School and Philips Exeter Academy before enrolling at Harvard University, where he studied American literature and history. Vesell then earned a medical degree from Harvard Medical School and completed postdoctoral research at Rockefeller University. After a stint at Peter Bent Brigham Hospital, Vesell worked for the National Institutes of Health. George T. Harrell invited Vesell to join the faculty of Pennsylvania State University in 1968 as founding chair of the Department of Pharmacology. He was appointed to the Bernard B. Brodie Professorship, followed by PSU most prestigious title, the Evan Pugh Professorship, in 1981. In 1990, he was made a fellow of the American Association for the Advancement of Science. Vesell stepped down as pharmacology department chair in 2004, and was succeeded by Kent Vrana in an endowment named for Vesell. Vesell retired from Penn State in December 2008, and died on July 23, 2018, aged 84.

(See a Problem?)

Elliot Vesell's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The antipyrine test in clinical pharmacology: Conceptions and misconceptions (1979) (366)
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. (1969) (266)
Genetic Control of Drug Levels in Man: Antipyrine (1968) (250)
Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. (1975) (224)
Genetic and environmental factors affecting ethanol metabolism in man (1971) (217)
Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. (1974) (202)
Genetic Control of Drug Levels in Man: Phenylbutazone (1968) (176)
Localization of Lactic Acid Dehydrogenase Activity in Serum Fractions (1957) (174)
Genetic control of dicumarol levels in man. (1968) (154)
Impairment of drug metabolism in man by allopurinol and nortriptyline. (1970) (152)
Induction of Drug-Metabolizing Enzymes in Liver Microsomes of Mice and Rats by Softwood Bedding (1967) (150)
Metabolism of nicotine. (1991) (141)
Genetic and environmental factors affecting drug disposition in man (1977) (140)
Genetic Variation as a Guide to Drug Development (1998) (140)
Smoking‐induced changes in nicotine disposition: Application of a new HPLC assay for nicotine and its metabolites (1982) (139)
Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. (1976) (138)
Isozymes of lactic dehydrogenase in human tissues. (1961) (132)
Disposition of nicotine and eight metabolites in smokers and nonsmokers: Identification in smokers of two metabolites that are longer lived than cotinine (1990) (124)
From Human Genetics and Genomics to Pharmacogenetics and Pharmacogenomics: Past Lessons, Future Directions (2008) (106)
Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. (1988) (98)
Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. (1976) (97)
Factors altering the responsiveness of mice to hexobarbital. (1968) (96)
Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration (1974) (95)
Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. (1977) (91)
Pharmacogenetic perspectives gained from twin and family studies. (1989) (90)
Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. (2004) (90)
The roles of synthesis and degradation in determining tissue concentrations of lactate dehydrogenase-5. (1969) (89)
Altered plasma half‐lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction (1975) (89)
Temporal variations in acetaminophen and phenacetin half‐life in man (1975) (85)
Pharmacogenomics and “Individualized Drug Therapy” (2003) (82)
Indomethacin Disposition and Indomethacin‐Induced Platelet Dysfunction in Premature Infants (1978) (81)
Lactate Dehydrogenase Isozymes: Kinetic Properties at High Enzyme Concentrations (1970) (79)
Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation. (1983) (78)
Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. (2003) (76)
Impairment of drug metabolism by disulfiram in man (1971) (76)
Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. (1988) (76)
SIGNIFICANCE OF THE HETEROGENEITY OF LACTIC DEHYDROGENASE ACTIVITY IN HUMAN TISSUES * (1961) (76)
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. (2008) (74)
Comparative study of methods for quantitation of lactate dehydrogenase isozymes. (1970) (72)
Observations on the heterogeneity of malic and lactic dehydrogenase in human serum and red blood cells. (1958) (70)
Heterogeneity of N-and O-methyltransferases. (1970) (69)
Inhibition of drug metabolism in man. (1973) (68)
Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. (1979) (68)
Hepatic Drug Metabolism in Rats: Impairment in a Dirty Environment (1973) (66)
Polymorphism of theophylline metabolism in man. (1985) (65)
Variations in the Lactic Dehydrogenase of Vertebrate Erythrocytes (1962) (64)
On the significance of host factors that affect drug disposition (1982) (63)
Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. (1977) (62)
Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. (1981) (61)
Genetic and environmental influence on halothane metabolism in twins (1971) (61)
Lactate and pyruvate concentrations in exercised ischemic canine muscle: relationship of tissue substrate level to lactate dehydrogenase isozyme pattern. (1966) (59)
Advances in pharmacogenetics. (1973) (58)
Species differences in inducibility of phenylethanolamine-N-methyl transferase. (1968) (58)
Sex differences in absorption kinetics of sodium salicylate (1982) (58)
Relationship between plasma antipyrine half-lives and hepatic microsomal drug metabolism in dogs. (1973) (57)
Studies on theobromine disposition in normal subjects; Alterations induced by dietary abstention from or exposure to methylxanthines (1978) (56)
Environmental and genetic factors affecting the response of laboratory animals to drugs. (1976) (56)
Reduced drug elimination in congestive heart failure. Studies using aminopyrine as a model drug. (1978) (55)
Underrepresentation of women in new drug trials. (1981) (54)
Aminopyrine disposition: Studies on breath, saliva, and urine of normal subjects and patients with liver disease (1976) (53)
A new quantitative thermospray LC-MS method for nicotine and its metabolites in biological fluids. (1990) (53)
Metabolism of nicotine by hepatocytes. (1990) (53)
Liquid Chromatographic Assay of Warfarin: Similarity of Warfarin Half-Lives in Human Subjects (1974) (52)
Underrepresentation of women in clinical drug trials (1993) (51)
COMPARATIVE STUDIES OF THE ISOZYMES OF LACTIC DEHYDROGENASE IN RABBIT AND MAN (1962) (51)
Isozymes of lactice dehydrogenase; their alterations in arthritic synovial fluid and sera. (1962) (51)
GENETIC AND ENVIRONMENTAL FACTORS AFFECTING HEXOBARBITAL METABOLISM IN MICE (1968) (50)
Genetic control of chloroform toxicity in mice (1975) (49)
Antipyrine metabolism during the menstrual cycle (1980) (49)
Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response. (1979) (48)
Disposition of Morphine in Man (1971) (47)
Genetic control of isozyme patterns in human tissues. (1965) (46)
Concentration-dependent effects of fatty acids on warfarin binding to albumin. (1977) (46)
Effect of cooking methods on the mutagenicity of food and on urinary mutagenicity of human consumers. (1989) (46)
Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. (2006) (45)
Polymorphism of Human Lactate Dehydrogenase Isozymes (1965) (45)
Further Observations on Relationships between Antipyrine Half-life, Clearance and Volume of Distribution: An Appraisal of Alternative Kinetic Parameters Used to Assess the Elimination of Antipyrine (1980) (45)
Symphalangism, strabismus and hearing loss in mother and daughter. (1960) (44)
Complex effects of diet on drug disposition (1984) (44)
Failure of Indomethacin and Warfarin to Interact in Normal Human Volunteers (1975) (43)
Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. (1975) (43)
Sequential Alterations of Lactic Dehydrogenase Isozymes During Embryonic Development and in Tissue Culture.∗ (1962) (43)
Chloroform toxicity in the mouse: role of genetic factors and steroids. (1979) (43)
Significance of error associated with use of the one‐compartment formula to calculate clearance of thirty‐eight drugs (1978) (42)
Unaltered metabolism of antipyrine and tolbutamide in fasting man (1975) (41)
Radioimmunoassay of plasma nicotine in habituated and naive smokers (1974) (40)
Drug Metabolism in Man (1971) (39)
Effects of various barbiturates on hepatic microsomal enzymes. A comparative study. (1974) (38)
Temporal variations of antipyrine half‐life in man (1977) (37)
Lactate Dehydrogenase Isozymes: Substrate Inhibition in Various Human Tissues (1965) (36)
Lactate Dehydrogenase Isozyme Patterns of Human Platelets and Bovine Lens Fibers (1965) (36)
Radiometric-high-performance liquid chromatographic assay for nicotine and twelve of its metabolites. (1987) (36)
High levels of methylxanthines in chocolate do not alter theobromine disposition (1985) (36)
Twin studies in pharmacogenetics. (1978) (35)
Factors causing interindividual variations of drug concentrations in blood (1974) (35)
Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. I. Analysis, characterization and regulation of specific beta adrenergic receptors. (1987) (34)
Lactate Dehydrogenase Isozymes: Substrate Inhibition in Various Human Tissues (1965) (34)
Multiple molecular forms of enzymes. Introduction. (1968) (33)
Genetic and environmental factors affecting drug response in man. (1972) (33)
Relationship Between Drug Distribution and Therapeutic Effects in Man (1974) (33)
Are the Elderly Underrepresented in Clinical Drug Trials? (1999) (32)
BIOLOGICAL APPLICATIONS OF LACTIC DEHYDROGENASE ISOZYMES: CERTAIN METHODOLOGICAL CONSIDERATIONS * (1964) (31)
Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe. (1995) (31)
Disposition of morphine in man. (1972) (31)
Lactate dehydrogenase isozymes. Turnover in rat heart, skeletal muscle, and liver. (1973) (31)
pH Dependence of Lactate Dehydrogenase Isozyme Inhibition by Substrate (1966) (31)
New theory of the control of protein concentrations in animal cells. (1971) (31)
Therapeutic Lessons from Pharmacogenetics (1997) (30)
Nicotine metabolism in stumptailed macaques, Macaca arctoides. (1991) (30)
ETHANOL METABOLISM: REGULATION BY GENETIC FACTORS IN NORMAL VOLUNTEERS UNDER A CONTROLLED ENVIRONMENT AND THE EFFECT OF CHRONIC ETHANOL ADMINISTRATION (1972) (29)
Cimetidine‐induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites (1984) (29)
Effects of pH, ionic strength, and metabolic intermediates on the rates of heat inactivation of lactate dehydrogenase isozymes. (1966) (29)
Genetic and environmental factors causing variation in drug response. (1991) (28)
Variables affecting nicotine metabolism. (1993) (28)
Enhanced drug-metabolizing capacity within liver adjacent to human and rat liver tumors. (1980) (28)
Sources of interindividual variations in acetaminophen and antipyrine metabolism (1984) (27)
EFFECTS OF DRUGS AND DRUG METABOLITES ON ERYTHROCYTES FROM NORMAL AND GLUCOSE‐6‐PHOSPHATE DEHYDROGENASE‐DEFICIENT INDIVIDUALS (1968) (27)
Receptor-independent sequestration of beta-adrenergic ligands by alveolar type II cells. (1986) (27)
Identification of radiolabeled metabolites of nicotine in rat bile. Synthesis of S-(-)-nicotine N-glucuronide and direct separation of nicotine-derived conjugates using high-performance liquid chromatography. (1993) (26)
Studies on rates of abortive ternary complex formation of lactate dehydrogenase isozymes. (1969) (25)
Effects of chronic parenteral carbohydrate administration on hepatic drug metabolism in the rat. (1979) (25)
Pharmacogenetic Perspectives: Genes, Drugs and Disease (1984) (25)
Reduced warfarin binding of albumin variants. (1977) (24)
Sex and strain differences in basal and induced aniline hydroxylase and ethylmorphine N-demethylase activities from domestic and wild rats. (1969) (23)
Metabolism and disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) in rhesus monkeys. (1999) (23)
GENETIC AND ENVIRONMENTAL FACTORS AFFECTING HEXOBARBITAL METABOLISM IN MICE (1968) (23)
Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine. (1975) (22)
HLA antigens influence resistance to lung carcinoma. (1991) (22)
Genetic risk prediction: individualized variability in susceptibility to toxicants. (2013) (22)
Reproducibility of individual rates of ethanol metabolism in fasting subjects (1990) (22)
From progress to regression: biomedical research funding. (2004) (22)
Effects of buffer,pH, ionic strength and temperatures on lactate dehydrogenase isozymes. (1968) (22)
Effect of Dilution on the Lactic Dehydrogenase Isozyme Pattern obtained in the Starch Gel (1962) (22)
Dietary patterns and diurnal variations in aminopyrine disposition (1981) (22)
Localization of a Lactic Dehydrogenase Isozyme in Nuclei of Young Cells in the Erythrocyte Series.∗ (1962) (22)
Recent progress in pharmacogenetics. (1969) (21)
Electrophoretic properties of dopamine -hydroxylase in several tissues from three species. (1972) (21)
Bernard B. Brodie and the rise of chemical pharmacology. (1989) (21)
The model drug approach in clinical pharmacology (1991) (21)
Studies on theophylline metabolism: Autoinduction and inhibition by antipyrine (1987) (21)
Diurnal rhythms of aminopyrine metabolism: Failure of sleep deprivation to affect them (1978) (20)
Effects of various centrally active drugs on hepatic microsomal enzymes: a comparative study. (1973) (20)
CONCLUSIONS, RESEARCH NEEDS, AND RECOMMENDATIONS OF THE EXPERT PANEL: TECHNICAL WORKSHOP ON HUMAN MILK SURVEILLANCE AND RESEARCH FOR ENVIRONMENTAL CHEMICALS IN THE UNITED STATES (2002) (20)
Therapeutic drug monitoring (1988) (20)
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. (1971) (19)
Laurence-Moon-Biedl syndrome. Report of an unusual family. (1961) (19)
Genetic control of interindividual variations in racemic warfarin binding to plasma and albumin of twins (1977) (19)
Do histocompatibility antigens antigence influence the risk of head and neck carcinoma? (1992) (19)
On the antipyrine test in laboratory animals. Studies in the dog and monkey. (1989) (19)
PROTECTION OF LACTATE DEHYDROGENASE ISOZYMES FROM HEAT INACTIVATION AND ENZYMATIC DEGRADATION (1968) (19)
Hormonal regulation of the developmental pattern of epoxide hydrolases. Studies in rat liver. (1989) (18)
Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease; Combined use of laboratory tests to study disease‐induced alterations in drug disposition (1977) (18)
Interaction between antipyrine and aminopyrine (1976) (18)
Noninvasive Assessment In Vivo of Hepatic Drug Metabolism in Health and Disease (1984) (18)
Genetic and environmental factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. (1989) (18)
Studies on the metabolism of aminopyrine, antipyrine and theophylline using monoclonal antibodies to cytochrome P-450 isozymes purified from rat liver. (1987) (17)
Evidence for post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. (1972) (17)
A sensitive gas-chromatographic assay using a nitrogen-phosphorus detector for determination of antipyrine and aminopyrine in biological fluids. (1979) (17)
Sounding board. Why are toxic reactions to drugs so often undetected initially? (1980) (16)
The Pursuit of Clinical Truth: Role of Epidemiology/Observation Studies (2000) (16)
Declines in NIH R01 Research Grant Funding (2008) (16)
MEDICAL USES OF ISOZYMES (1975) (16)
Selection of subjects for investigation of host factors affecting drug response: A method to identify new pharmacogenetic conditions (1984) (16)
Multiple molecular forms of enzymes. (1969) (16)
Effects of chronic prazepam administration on drug metabolism in man and rat. (1972) (16)
Unusual characteristics of the dose-dependent uptake of propylthiouracil by thyroid gland in vivo. Effects of thyrotropin, iodide or phenobarbital pretreatment. (1979) (16)
Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile. (1993) (16)
Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor. (1978) (15)
Why individuals vary in their response to drugs (1980) (15)
Declines in Funding of NIH R01 Research Grants (2006) (14)
Influence of different forms of tobacco intake on nicotine elimination in man. (1983) (14)
Comparative studies of the mutagenicity of urine from smokers and non-smokers on a controlled non-mutagenic diet. (1990) (14)
Hydrochlorothiazide‐Induced 131I Excretion Facilitated by Salt and Water (1981) (14)
Anomalous results of studies on drug interaction in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin. (1975) (14)
Further studies on post-transcriptional stabilization of ribosomal precursor ribonucleic acid by phenobarbital. (1974) (13)
Women in Clinical Drug Trials (1994) (13)
Pharmacology and Statistics: Recommendations to Strengthen a Productive Partnership (2006) (13)
Genetic control of chloroform toxicity in mice. (1976) (13)
Inhibition of urea transport across renal tubules by pyrazinoylguanidine and analogs. (1992) (13)
Lactate Dehydrogenase Isozymes: Further Kinetic Studies at High Enzyme Concentration (1970) (13)
Effects of metabolites of primaquine and acetanilid on normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. (1968) (13)
Environmental and genetic factors affecting laboratory animals: impact on biomedical research. Introduction. (1976) (12)
Do histocompatibility antigens influence the risk of head and neck carcinoma? (1992) (12)
Limitations of probit plots in pharmacogenetics: requirement of genetic analyses to test hypotheses based on graphical methods. (1995) (12)
Studies of a methionine-activating enzyme. (1972) (12)
Lactate Dehydrogenase Isozymes: Further Kinetic Studies at High Enzyme Concentration (1971) (12)
Implications for Risk Assessment of Host Factors Causing Large Pharmacokinetic Variations (1985) (12)
Pyrazinoylguanidine: Antihypertensive, Hypocholesterolemic, and Renin Effects (1992) (11)
Genetic and environmental factors affecting host response to drugs and other chemical compounds in our environment. (1977) (11)
Aminopyrine disposition: a sensitive index of acetaminophen-induced hepatocellular damage. (1978) (11)
Disease as one of many variables affecting drug disposition and response: alterations of drug disposition in liver disease. (1978) (11)
Which Studies of Therapy Merit Credence? Vitamin E and Estrogen Therapy as Cautionary Examples (2002) (10)
Anomalous results of studies on drug interaction in man. I. Nortriptyline and antipyrine. (1975) (10)
Polygenic factors controlling drug response. (1974) (9)
Pharmacogenetic perspectives on susceptibility to toxic industrial chemicals. (1987) (9)
Intraspecies differences in frequency of genes directly affecting drug disposition: the individual factor in drug response. (1978) (9)
Variations in Aryl Hydrocarbon Hydroxylase Activities in Mitogen-Activated Human and Nonhuman Primate Lymphocytes (1984) (9)
Phenobarbital-induced increases in methylation of ribosomal precursor ribonucleic acid. (1976) (9)
Gene-Environment Interactions in Drug Metabolism (1980) (9)
Interactions of drugs of abuse (1976) (9)
Genetically Determined Variations in Drug Disposition and Response in Man (1975) (9)
Formation of human lactate dehydrogenase isozyme patterns in vitro. (1965) (9)
Interaction of pargyline with rat hepatic microsomes. (1978) (9)
Comparative stimulatory effects of four phenothiazines on hepatic microsomal enzymes. (1974) (8)
Reproducibility of antipyrine half‐lives in elderly subjects (1993) (8)
Heterogeneous response of hepatic mixed function oxidases to chronic phenobarbital administration. (1979) (8)
New directions in pharmacogenetics: Introduction. (1984) (7)
The Power of Pharmacological Sciences: The Example of Proton Pump Inhibitors (2006) (7)
The Heart of Drug Discovery and Development: Rational Target Selection (2006) (7)
Studies on Pyrazinoylguanidine (1996) (7)
A Rational Approach to the Selection of Useful Drugs for Clinical Practice (2002) (7)
Pharmacokinetics of pyrazinoyl-guanidine, 3-aminopyrazinoyl-guanidine and their corresponding pyrazinoic acid metabolites in humans and dogs. (1992) (7)
Interactions of beta adrenergic antagonists with isolated rat alveolar type II pneumocytes. II. Receptor-independent accumulation of beta adrenergic antagonists and other cationic amphiphilic drugs in lamellar bodies. (1987) (7)
A new polymorphism of hepatic drug oxidation in humans: family studies of antipyrine metabolites. (1984) (7)
Time-dependent induction of hepatic drug metabolism in rats by cotinine. (1983) (6)
Contrasting Effects of Pyrazinoylguanidine and Hydrochlorothiazide in Patients with Renal Insufficiency (1993) (6)
Genetic and Environmental Factors Responsible for Interindividual Variations in Drug Response (1979) (6)
Polymorphisms of antipyrine and theophylline metabolism in man: molecular and clinical implications. (1986) (6)
New directions in pharmacogenetics (1984) (6)
New approaches to assessment of drug disposition in the surgical patient. (1984) (6)
Studies on the interaction of several boron hydrides with liver microsomal enzymes. (1974) (6)
MOLECULAR BIOLOGY OF PHENOBARBITAL ACTIONS AND INTERACTIONS (1976) (6)
Further studies on the increase in drug-metabolizing capacity adjacent to intrahepatic Morris hepatomas. (1981) (6)
Clinical pharmacology: A personal perspective (1985) (6)
In vivo and in vitro biotransformation of theobromine by phenobarbital- and 3-methylcholanthrene-inducible cytochrome P-450 monooxygenases in rat liver. Role of thiol compounds. (1987) (6)
Urinary test for a metabolite of prochlorperazine. (1959) (5)
Studies on pyrazinoylguanidine. 6. Prevention of cataracts in STZ-diabetic rats. (1997) (5)
Strain differences in uptake, pool size and turnover rate of norepinephrine in hearts of mice. (1970) (5)
Genetic host factors: determinants of drug response. (1985) (5)
CHAPTER 14 – Intraindividual and Interindividual Variations* (1983) (5)
Pyrazinoylguanidine Downregulates the Glucose Fatty‐Acid Cycle in Hypertensive, Hyperinsulinemic Diabetic Patients (1994) (5)
Genetic and environmental factors affecting the metabolism of carcinogens. (1980) (5)
Crisis in NIH funding. (1982) (5)
Basic requirements for in vitro metabolic activation systems in mutagenesis testing. (1980) (4)
Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes. (1996) (4)
Basal and paracetamol-depleted glutathione from human lymphocytes: ethnic variability. (1994) (4)
Pharmacogenetic approaches to the prediction of drug response. (1986) (4)
EFFECTS OF DRUGS AND DRUG METABOLITES ON ERYTHROCYTES FROM NORMAL AND GLUCOSE‐6‐PHOSPHATE DEHYDROGENASE‐DEFICIENT INDIVIDUALS (1968) (4)
Dynamic interactions among host factors that influence antipyrine metabolism: implications for the design and interpretation of studies on ethnic pharmacokinetic variations. (1986) (4)
The influence of host factors on drug response. I. Ethnic background. (1979) (4)
Elucidation of the pharmacokinetic interaction between acutely administered ethanol and benzodiazepines. (1980) (4)
Corrigendum to “Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead” [Eur. J. Pharmacol. 500 (2004) 267–280] (2005) (4)
Studies on pyrazinoylguanidine. 1. Characterization of metabolic effects in diabetic rats. (1996) (4)
The influence of host factors on drug response. III. Diet. (1980) (4)
CHAPTER 12 – Inhibition of Isozymes (1972) (4)
Fundamentals of Drug Metabolism and Drug Disposition. Bert N. La Du, H. George Mandel, and E. Leong Way, Eds. Williams & Wilkins Co., Baltimore, Md. 21202,1971, xvii + 615 pp. $19.75 (1972) (4)
Differential effects of phenobarbital and 3-methylcholanthrene on rat hepatic ribosomal precursor RNA. (1977) (4)
Hormonal and immunological regulation of 2', 5'-oligoadenylate synthetase activity in human peripheral blood mononuclear cells. (1992) (3)
Pharmacogenetic application of methods from population genetics (1987) (3)
Studies on pyrazinoylguanidine. 4. Upregulation of phosphodiesterase activity in rat adipose tissue and downregulation of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver. (1996) (3)
Studies on pyrazinoylguanidine. 2. Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats. (1996) (3)
Reflections from distant cuvettes. (1996) (3)
The influence of host factors on drug response. II, Age. (1980) (3)
Clinical pharmacology: a new specialty. (1981) (3)
Genetic factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes. (1991) (3)
Studies on pyrazinoylguanidine. 7. Effects of single oral doses in normal human subjects. (1999) (3)
Normal antipyrine metabolism in patients with cholesterol cholelithiasis (2005) (3)
Authors’ Index Vol. 10, 1973 (1973) (3)
Proceedings: Genetic factors affecting response to psychopharmacological agents. (1974) (2)
Induction of Drug-Metabolizing Enzymes in Liver Microsomes of Mice and Rats by Softwood Bedding (1967) (2)
Brief maternal deprivation of rats reduces hepatic mixed function oxidase activities. (1989) (2)
The influence of host factors on drug response. V. Endocrinological, gastrointestinal, and pulmonary diseases. (1981) (2)
Alterations in normal and G-6-PD deficient human erythrocytes of various ages after exposure to metabolites of hemolytic drugs. (1971) (2)
Complex, dynamically interacting host factors that affect the disposition of drugs and carcinogens. (1982) (2)
Studies on pyrazinoylguanidine: a novel antihypertensive, hypoglycemic and lipolytic drug intended for adjunctive use in hypertensive patients with type 2 diabetes mellitus. (2000) (2)
EFFECTS OF DISEASE STATES ON DRUG DISPOSITION IN MAN (1977) (2)
Complex interactions between drugs and dietary factors. (1986) (2)
The influence of host factors on drug response. VII. Implications for interpretation of clinical trials and other published studies on drug response in man. (1981) (2)
Biomedical Research Funding: View of the National Caucus of Basic Biomedical Science Chairs (1992) (2)
250 INDOMETHACIN DISPOSITION IN PREMATURE INFANTS: BLEEDING DUE TO PLATELET DYSFUNCTION AFTER SINGLE DOSES OF INDOMETHACIN (1978) (1)
Effect of Dietary Factors on Drug Disposition in Normal Human Subjects (1985) (1)
Pharmacogenetics and Pharmacogenomics: Recent Conceptual and Technical Advances (2000) (1)
Factors Affecting the Activity, Tissue Distribution, Synthesis and Degradation of Isozymes1 (1971) (1)
Pharmacogenetics--the individual factor in drug response. (1975) (1)
Recent progress in pharmacogenetics. (1969) (1)
Genetic and environmental factors affecting hexobarbital induced sleeping time (st) in mice. Abstr. (1968) (1)
Studies on pyrazinoylguanidine. 5. Temporal effects over 24 weeks demonstrating attenuation of diabetic nephropathy in STZ-diabetic rats. (1997) (1)
Pedigree Analysis of a Subject with Abnormally Slow Renal Elimination of 6-Hydroxychlorzoxazone (1998) (1)
The influence of host factors on drug response. VI. Hepatocellular diseases. (1981) (1)
Contents Vol. 61, 2000 (2000) (1)
~ETA~~LIS~ OF NICOTINE BY HEPATOCYTES (1990) (0)
Do HLA antigens influence risk of lung cancer (1991) (0)
NIH Funding (1989) (0)
Book Reviews: Yesterday's Children: The Antiques and History of Child Care By S Kevill-Davies, 315 pp, $49.95, Woodbridge, Suffolk, England, Antique Collectors' Club, 1991 (1993) (0)
Contents, Vol. 13, 1975 (1975) (0)
Pyrazinoylguanidine in End-Stage Renal Disease: A Prospective, Placebo-Controlled Pilot Study (1998) (0)
Pharmacogenetics and encainide (1985) (0)
Recollections from the Kunkel Laboratory, 1956-1958 (2003) (0)
Further comments regarding drug disposition in the surgical patient. (1985) (0)
PREFACE (1976) (0)
Acute Tubular Lesions, Kidney, Rat (1986) (0)
Pharmacogenetics and Pediatrics (1973) (0)
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6th ed. A. G. Oilman, L. S. Goodman, and A. Gilman, Eds., Macmillan Publishing Co., New York, NY 10022. xvi + 1843 pp. Pub. August 1980. $45.00 (1981) (0)
Subject Index Vol. 10, 1973 (1973) (0)
Introduction to a New Review Section (2000) (0)
The influence of host factors on drug response. IV. Occupation. (1980) (0)
The influence of host factors on drug response. VII. Renal diseases. (1981) (0)
Introduction (2000) (0)
Pharmacogenetic differences between humans and laboratory animals: implications for modelling (2020) (0)
Interindividualand IntraindividualVariationsin Aryl HydrocarbonHydroxylasein Monocytesfrom Monozygoticand DizygoticTwins (1977) (0)
Science and Social Responsibility: Incidents from the Lives of J. B. S. Haldane and Otto Krayer (2015) (0)
Drug interactions: quinine antipyrine and quinine quinine (1974) (0)
A committee report on vacant chairs of pharmacology. (1991) (0)
Editorial (2000) (0)
Subject Index Vol. 8, 1972 (1972) (0)
Contents, Vol. 10, 1973 (1973) (0)
Immunoassays for Drugs Subject to Abuse. S. J. Mulé, I. Sunshine, M. Braude, and R. E. Willette, Eds. CRC Press, 18901 Cranwood Parkway, Cleveland, Ohio 44128, 1974, ix + 126 pp. $ 23.00 (1975) (0)
Application of pharmacokinetic principles to the elucidation of polygenically controlled differences in drug response (1973) (0)
Results, Intent and Aim (1970) (0)
INTRODUCTION (1968) (0)
Genetic and environmental causes of variability in drug response (1990) (0)
Contents, Vol. 2, 1969 (1969) (0)
Subject Index Vol. 13, 1975 (1975) (0)
Drugs and Twins (1968) (0)
545 – THE INDIVIDUAL FACTCR IN DRUG RESPONSE (1978) (0)
Reply (1991) (0)
Subject Index Vol. 61, 2000 (2000) (0)
6.1-04 Do HLA antigens influence resistance to lung carcinoma? (1989) (0)
Book Reviews / Instructions to Authors (1972) (0)

This paper list is powered by the following services:

Other Resources About Elliot Vesell

en.wikipedia.org

What Schools Are Affiliated With Elliot Vesell?

Elliot Vesell is affiliated with the following schools: